Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2014-04-28 | C. Geoffrey McDonough, M.D. Director Age 43 Mr. McDonough has served as a member of our Board since November 2012. Since August 2011, Mr. McDonough has served as President and Chief Executive Officer of Swedish Orphan Biovitrum AB (Sobi), a Swedish pharmaceutical company. Prior to joining Sobi, Mr. McDonough held several senior leadership positions at Genzyme Corporation from 2002 to June 2011, including Senior Vice President and General Manager, Personalized Genetic Health, Senior Vice President, Lysosomal Storage Disease (LSD) Therapeutics and most recently, as President of Europe, Middle East and Africa (EMEA). Prior to joining Genzyme, Mr. McDonough co-founded and served as President of Catalyst Medical Solutions, a developer of software for hospital management, and was a practicing internist and pediatrician. Mr. McDonough received a B.A. and a B.Sc. from the University of North Carolina at Chapel Hill and an M.D. from Harvard Medical School. We believe that Mr. McDonough is qualified to serve on our Board because of his extensive executive leadership experience and knowledge of our industry. |
| 2015-04-28 | C. Geoffrey McDonough, M.D. Director Age 44 Dr. McDonough has served as a member of our Board since November 2012. ... 2014 Director Compensation Table shows C. Geoffrey McDonough, M.D. received total compensation of $227,412. |
| 2016-04-28 | C. Geoffrey McDonough, M.D. Director Age 45 Dr. McDonough has served as a member of our Board since November 2012. Since August 2011, Dr. McDonough has served as President and Chief Executive Officer of Swedish Orphan Biovitrum AB (Sobi), a global biopharmaceutical company dedicated to rare diseases. Prior to joining Sobi, Dr. McDonough held several senior leadership positions at Genzyme Corporation, a biotechnology company, from 2002 to June 2011, including Senior Vice President and General Manager, Personalized Genetic Health, Senior Vice President, Lysosomal Storage Disease Therapeutics and most recently, as President of Europe, Middle East and Africa. Prior to joining Genzyme, Dr. McDonough co-founded and served as President of Catalyst Medical Solutions, a developer of software for hospital management, and was a practicing internist and pediatrician. Since 2015, Dr. McDonough has served on the board of directors of Zafgen, Inc., a biopharmaceutical company. Dr. McDonough received a B.A. and a B.Sc. from the University of North Carolina at Chapel Hill and an M.D. from Harvard Medical School. We believe that Dr. McDonough is qualified to serve on our Board because of his extensive executive leadership experience and knowledge of our industry. 2015 Director Compensation Table: C. Geoffrey McDonough, M.D. Fees earned or paid in cash $35,000 Option awards $359,801 All other compensation $0 Total $394,801 |
| 2017-04-28 | Dr. McDonough has served as a member of our Board since November 2012. |
Data sourced from SEC filings. Last updated: 2026-03-14